Ameritas Investment Partners’s Relmada Therapeutics RLMD Stock Holding History

Ameritas Investment Partners’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,926	Closed	-$4.35K	–	3195
2023 Q1	$4.35K	Hold	1,926	–	–	﹤0.01%	2885
2022 Q4	$8.51K	Hold	1,926	–	–	﹤0.01%	2846
2022 Q3	$71K	Hold	1,926	–	–	﹤0.01%	1732
2022 Q2	$36K	Hold	1,926	–	–	﹤0.01%	2209
2022 Q1	$52K	Buy	1,926 +684	+55%	+$14.1K	﹤0.01%	2048
2021 Q4	$28K	Hold	1,242	–	–	﹤0.01%	2482
2021 Q3	$33K	Hold	1,242	–	–	﹤0.01%	2419
2021 Q2	$40K	Hold	1,242	–	–	﹤0.01%	2336
2021 Q1	$44K	Hold	1,242	–	–	﹤0.01%	2164
2020 Q4	$40K	Hold	1,242	–	–	﹤0.01%	2112
2020 Q3	$47K	Hold	1,242	–	–	﹤0.01%	1880
2020 Q2	$56K	Buy	+1,242	New	+$52.5K	﹤0.01%	1761

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Ameritas Investment Partners's RLMD Position: Q2 2023 in Review

Ameritas Investment Partners sold out of Relmada Therapeutics (RLMD) in Q2 2023, closing a stake of 1,926 shares — an estimated $4.35K sold.

Ameritas Investment Partners first reported a position in RLMD in Q2 2020 and held it in 12 quarters. The position peaked at $71K in Q3 2022. 95 funds tracked by Wall St. Rank hold RLMD as of Q2 2023.

Ameritas Investment Partners reported no remaining Relmada Therapeutics position as of Q2 2023 after selling out during the quarter.
Ameritas Investment Partners sold 1,926 Relmada Therapeutics shares in Q2 2023, an estimated $4.35K.
Ameritas Investment Partners first reported a position in Relmada Therapeutics in Q2 2020 and held it in 12 quarters.
Ameritas Investment Partners's Relmada Therapeutics position peaked at $71K in Q3 2022.
95 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2023.

Based on Ameritas Investment Partners's 13F filing for Q2 2023, filed 11 Aug 2023.